Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values

AstraZeneca800 enrolled

Overview

This study is non-interventional study of patients who are treated with any HMGCoA reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in Bosnia and Herzegovina for at least 6 months. Data collection for each patient will take place at a single visit. The investigators will complete Case Report Form (CRF) with patient's demographic, the presence of the factors for high cardiovascular risk, current treatment, cholesterol value as well as with further treatment decision.

Non-interventional study to assess reaching of cholesterol target values in patients treated with HMG-CoA reductase inhibitors in Bosnia and Herzegovina

Study Type

OBSERVATIONAL

Enrollment

800

Conditions

Hypercholesterolaemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients, treated with one HMG-CoA reductase inhibitors for at least 6 months without changing the dose for the last 4 weeks at least * All patients must sign informed consent form Exclusion Criteria: * Patients who have not signed the Informed Consent Form * Patients with contraindication for the treatment with HMG-CoA reductase inhibitors as per SmPC approved in Bosnia and Herzegovina

Locations (14)

Research Site

Banja Luka, Bosnia and Herzegovina

Research Site

Bijeljina, Bosnia and Herzegovina

Research Site

Doboj, Bosnia and Herzegovina

Outcomes

Primary Outcomes

The number and percentage of patients reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline.

Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated

Secondary Outcomes

The number and percentage of patients reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline.

Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated

The number and percentage of patients with high cardiovascular risk reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline.

Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated

The number and percentage of patients with high cardiovascular risk reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline.

Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.